P5 Health Ventures

P5 Health Ventures, LLC is a venture capital firm established in 2015 and located in Fairfield, Connecticut. The firm specializes in investing in seed, early, and mid-stage health technology companies that focus on various aspects of healthcare, including disease management, consumer-driven healthcare, population health management, diagnostics, telehealth, remote monitoring, and nutrition. P5 Health Ventures aims to support innovations that enhance the accessibility and quality of healthcare while reducing costs. The firm is particularly interested in companies that effectively translate research and technology into practical healthcare solutions. Its investment strategy primarily targets opportunities within the United States.

David Eigen

Co-Founder and Managing Director

10 past transactions

Genialis

Series A in 2023
Genialis, Inc. is a computational precision medicine company that specializes in developing a web-based software platform for biological data management and analysis. Founded in 2015 and based in Houston, Texas, the platform provides a suite of visual analytics and bioinformatics tools, facilitating the storage, analysis, and sharing of biological data while ensuring transparency and security. The system automates primary analyses to enhance reproducibility and allows non-computational experts to access advanced downstream analyses. Genialis focuses on unraveling complex biology to identify actionable biomarkers, which aids pharmaceutical companies in developing effective drugs and diagnostics that improve treatment decisions. The company's efforts aim to enhance translational research and clinical development, ultimately benefiting patients and their families.

Clarapath

Series B in 2021
Clarapath, Inc. is a medical robotics company that specializes in automating laboratory processes for digital pathology applications. Founded in 2011 and headquartered in New York, the company has developed Section Star, an automated device that streamlines microtomy through a tape transfer method. Clarapath provides a range of services, including routine histology, pathology consultation, whole slide imaging, quantitative image analysis, and long-term data management. Its anatomic pathology laboratory caters to both human and animal digital pathology needs, serving academic researchers and clinical laboratories. The company aims to enhance the quality and efficiency of lab medicine while reducing costs and labor-related delays. By integrating its technologies, Clarapath facilitates real-time access to tissue samples, thereby standardizing and simplifying the histology process and improving safety and throughput in laboratory settings.

FIGUR8

Series A in 2021
Figur8, Inc. is a Boston-based company that specializes in developing advanced wearable sensors to monitor body movement as a biomarker for musculoskeletal (MSK) conditions. Founded in 2016 as a spin-off from MIT, Figur8 combines smart biosensors, intuitive software, and artificial intelligence to analyze MSK health data. The technology captures three-dimensional skeletal movement and muscle output, allowing for objective assessment of musculoskeletal performance and recovery. This innovative solution provides valuable insights throughout the entire care process, from injury to full recovery, ultimately reducing healthcare costs, improving access to treatment, and empowering patients to manage their own MSK health effectively.

Hawthorne Effect

Series A in 2021
Hawthorne Effect is a clinical trial data platform committed to enhancing the accessibility and convenience of clinical trials for all individuals. It achieves this through a proactive Visit Management System that strengthens the partnership between study sponsors and investigators, leveraging shared technology to ensure adherence to protocols and reduce data omissions. The platform integrates licensed healthcare professionals with advanced connected technology, facilitating decentralized clinical trials that improve efficiency and accuracy compared to traditional methods. By deploying specially trained healthcare providers, known as “HEROs,” Hawthorne Effect allows for patient visits to be conducted anywhere and at any time, thereby minimizing the risk of patients being lost to follow-up and ensuring comprehensive tracking of patient data.

Conversa Health

Series B in 2021
Conversa Health, Inc. specializes in patient relationship management solutions aimed at enhancing communication between patients and healthcare teams. The company's flagship offering, the Conversa Virtual Care and Communication Platform, streamlines patient engagement and improves health outcomes through automated, personalized messaging based on comprehensive patient profiles derived from electronic health records, biometric devices, and self-reported data. This platform enables health systems, pharmaceutical companies, and payers to shift from reactive communication to proactive engagement, facilitating better management of chronic conditions, acute discharges, and preventive care. Conversa also provides Digital Checkups, which generate tailored clinical questions and alerts based on individual patient data, and Conversa Connect, a patient profiling and health signals engine. Established in 2013 and headquartered in Portland, Oregon, with additional offices in New York, North Carolina, and California, Conversa Health serves a diverse clientele, including healthcare providers, health systems, and health technology companies.

Conversa Health

Series B in 2020
Conversa Health, Inc. specializes in patient relationship management solutions aimed at enhancing communication between patients and healthcare teams. The company's flagship offering, the Conversa Virtual Care and Communication Platform, streamlines patient engagement and improves health outcomes through automated, personalized messaging based on comprehensive patient profiles derived from electronic health records, biometric devices, and self-reported data. This platform enables health systems, pharmaceutical companies, and payers to shift from reactive communication to proactive engagement, facilitating better management of chronic conditions, acute discharges, and preventive care. Conversa also provides Digital Checkups, which generate tailored clinical questions and alerts based on individual patient data, and Conversa Connect, a patient profiling and health signals engine. Established in 2013 and headquartered in Portland, Oregon, with additional offices in New York, North Carolina, and California, Conversa Health serves a diverse clientele, including healthcare providers, health systems, and health technology companies.

Iterative Scopes

Seed Round in 2020
Iterative Scopes, Inc. is a Boston-based company founded in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and the life sciences sector, particularly in the areas of colorectal cancer and inflammatory bowel disease. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical health areas.

FIGUR8

Seed Round in 2019
Figur8, Inc. is a Boston-based company that specializes in developing advanced wearable sensors to monitor body movement as a biomarker for musculoskeletal (MSK) conditions. Founded in 2016 as a spin-off from MIT, Figur8 combines smart biosensors, intuitive software, and artificial intelligence to analyze MSK health data. The technology captures three-dimensional skeletal movement and muscle output, allowing for objective assessment of musculoskeletal performance and recovery. This innovative solution provides valuable insights throughout the entire care process, from injury to full recovery, ultimately reducing healthcare costs, improving access to treatment, and empowering patients to manage their own MSK health effectively.

Babyscripts

Series A in 2017
Babyscripts is a developer of a virtual maternity care platform aimed at enhancing prenatal and postpartum care for pregnant mothers. The company's three-tiered approach allows healthcare providers to deliver tailored, risk-specific care anytime and anywhere. The first tier features a mobile app that offers daily educational content and resources throughout pregnancy and the postpartum period. The second tier incorporates remote monitoring through medical devices, enabling patients to track health metrics like blood pressure and alerting providers to potential risks. This system facilitates the transition of care beyond traditional clinical settings, enabling providers to focus on higher-risk patients while automating routine care. The third tier fosters collaboration between care teams and insurers, addressing challenges in care coordination and access, ultimately improving health outcomes and reducing costs. Through its innovative platform, Babyscripts aims to eliminate maternal mortality and enhance access to quality care for all mothers.

Cohero Health

Series A in 2016
Cohero Health, Inc. is a digital respiratory health company that focuses on improving the management of asthma and chronic obstructive pulmonary disease (COPD). Founded in 2012 and based in New York, the company offers a proprietary connected health platform that combines sensor-based technology with a mobile application. This platform includes the BreatheSmart app, which provides customized medication reminders, records inhaler usage, and tracks lung function, symptoms, and environmental conditions over time. Cohero Health's product suite features mSpirometer lung function sensors and HeroTracker, a Bluetooth-enabled inhaler tracker that monitors both control and rescue medications. Additionally, BreatheSmart Connect serves as a Software-as-a-Service solution for remote patient monitoring and communication, enhancing coordination between patients and healthcare providers. By utilizing these tools, Cohero Health aims to improve medication adherence and overall health outcomes for individuals with respiratory conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.